https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-03 / Clin Transl Immunology 2020;9(3):e1117
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-03 / Clin Transl Immunology 2020;9(3):e11172020-03-03 00:00:002020-03-03 00:00:00Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 Mar;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 Mar;8(1)2020-03-01 00:00:002020-03-01 00:00:00T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 03;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 03;8(1)2020-03-01 00:00:002022-09-29 14:17:36Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-27 / Cancers (Basel) 2020 Feb;12(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-27 / Cancers (Basel) 2020 Feb;12(3)2020-02-27 00:00:002020-02-27 00:00:00Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Front Oncol 2020;10:187
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Front Oncol 2020;10:1872020-02-21 00:00:002020-02-21 00:00:00Immunotherapy in Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-1387
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-13872020-02-20 00:00:002020-02-20 00:00:00Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-07 / J Clin Oncol 38, 2020 (suppl 5; abstr 63)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-07 / J Clin Oncol 38, 2020 (suppl 5; abstr 63)2020-02-07 00:00:002020-08-31 08:23:53Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e188892020-02-01 00:00:002020-02-01 00:00:00Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / J Immunother Cancer 2020 02;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / J Immunother Cancer 2020 02;8(1)2020-02-01 00:00:002020-02-01 00:00:00TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S119
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S1192020-02-01 00:00:002020-12-09 09:48:40Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
